Sarcoidosis: TNF-α release from alveolar macrophages and serum level of sIL-2R are prognostic markers

American Journal of Respiratory and Critical Care Medicine

Volumn 156, Issue 5, 1997, Pages 1586-1592

  Ziegenhagen, Manfred W ^a   Benner, Udo K ^b   Zissel, Gernot ^b   Zabel, Peter ^b   Schlaak, Max ^b   Müller Quernheim, Joachim ^b  

^a RESEARCH CENTER BORSTEL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 2 RECEPTOR; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SARCOIDOSIS; T LYMPHOCYTE;

EID: 0030711012     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.156.5.97-02050     Document Type: Article

References (35)

1. Hunninghake, G. W., and R. G. Crystal. 1981. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N. Engl. J. Med. 305:429-434.
2. Thomas, P. D., and G. W. Hunninghake. 1987. Current concepts of pathogenesis of sarcoidosis. Am. Rev. Respir. Dis. 135:747-760.
3. Müller-Quernheim, J., S. Pfeifer, D. Männel, J. Strausz, and R. Ferlinz. 1992. Lung restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis. Am. Rev. Respir. Dis. 145:187-192.
4. Müller-Quernheim, J., C. Saltini, P. Sondermeyer, and R. G. Crystal. 1986. Compartmentalized activation of the interleukin-2 gene by lung T-lymphocytes in active pulmonary sarcoidosis. J. Immunol. 137:3475-3483.
5. Robinson, B. W. S., T. McLemore, and R. G. Crystal. 1985. γ interferon is spontaneously released by alveolar macrophages and lung T-lymphocytes in patients with pulmonary sarcoidosis. J. Clin. Invest. 75: 1488-1495.
6. Hudspith, B. N., K. C. Flint, D. Geraint-James, J. Brostoff, and N. M. Johnson. 1987. Lack of immune deficiency in sarcoidosis: compartmentalisation of the immune response. Thorax 42:250-255.
7. Homolka, J., J. Lorenz, H. D. Zuchhold, and J. Müller-Quernheim. 1992. Evaluation of soluble CD14 and serum neopterin as serum parameters of inflammatory activity of pulmonary sarcoidosis. Clin. Invest. 70:909-916.
8. Gilbert, S., D. S. Steinbrech, S. K. Landas, and G. W. Hunninghake. 1993. Amounts of angiotensin-converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease. Am. Rev. Respir. Dis. 148:483-486.
9. Lawrence, E. C., K. P. Brousseau, M. B. Berger, C. C. Kurman, L. Marcon, and D. L. Nelson. 1988. Elevated concentration of soluble interleukin-2 receptors in serum samples and bronchoalveolar fluids in active sarcoidosis. Am. Rev. Respir. Dis. 137:759-764.
10. Müller-Quernheim, J., S. Pfeifer, J. Strausz, and R. Ferlinz. 1991. Correlation of clinical and immunologic parameters of the inflammatory activity of pulmonary sarcoidosis. Am. Rev. Respir. Dis. 144:1322-1329.
11. Hunninghake, G. W., S. Gilbert, R. Pueringer, C. Dayton, C. Floerchinger, R. Helmers, R. Merchant, J. Wilson, J. Galvin, and D. Schwartz. 1994. Outcome of the treatment of sarcoidosis. Am. J. Respir. Crit. Care Med. 149:893-898.
12. World Association of Sarcoidosis and other Granulomatous Disorders. 1994. Consensus conference: activity of sarcoidosis. Eur. Respir. J. 7: 624-627.
13. American Thoracic Society. 1995. Standardization of spirometry - 1994 update. Am. J. Respir. Crit. Care Med. 152:1107-1136.
14. American Thoracic Society. 1995. Single-breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique - 1995 update. Am. J. Respir. Crit. Care Med. 152:2185-2198.
15. Costabel, U., K. J. Bross, and H. Matthys. 1985. The immunoperoxidase slide assay: a new method for demonstration of surface antigens on bronchoalveolar lavage cells. Bull. Eur. Physiopathol. Respir. 21:381-387.
16. American Thoracic Society. 1990. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis and selected comparison groups. Am. Rev. Respir. Dis. 141:S167-S202.
17. Kist, A., A. D. Ho, U. Räth, B. Wiedenmann, A. Bauer, E. Schlick, H. Kirchner, and D. N. Männel. 1988. Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor. Blood 72:344-348.
18. Walker, C., W. Bauer, R. Braun, G. Menz, P. Braun, F. Schwarz, T. Hansel, and B. Villiger. 1994. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am. J. Respir. Crit. Care Med. 150:1038-1048.
19. Baughman, R. P., S. A. Strohofer, J. Buchsbaum, and E. E. Lower. 1990. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J. Lab. Clin. Med. 115:36-42.
20. 2 release, alveolitis, and disease severity in sarcoidosis. Chest 103: 832-838.
21. Zissel, G., J. Homolka, J. Schlaak, M. Schlaak, and J. Müller-Quernheim. 1996. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 154: 713-719.
22. Müller-Quernheim, J., S. Pfeifer, K. Kienast, and G. Zissel. 1996. Spontaneous interleukin-2 release of bronchoalveolar lavage cells in sarcoidosis is a co-determinator of prognosis. Lung 174:243-253.
23. Bjermer, L., L. Rosenhall, T. Angström, and R. Hällgren. 1988. Predictive value of bronchoalveolar lavage cell analysis in sarcoidosis. Thorax 43:284-288.
24. Buchalter, S., W. App, L. Jackson, D. Chandler, R. Jackson, and J. Fulmer. 1986. Bronchoalveolar lavage cell analysis in sarcoidosis: a comparison of lymphocyte counts and clinical course. Ann. N.Y. Acad. Sci. 465:678-684.
25. Verstraeten, A., M. Demedts, J. Verwilghen, A. van den Eeckhout, G. Marien, L. M. Lacquet, and J. L. Ceuppens. 1990. Predictive value of bronchoalveolar lavage in pulmonary sarcoidosis. Chest 98:560-567.
26. Ward, K., C. O'Connor, C. Odlum, and M. X. Fitzgerald. 1989. Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation. Thorax 44:6-12.
27. Keogh, B. A., G. W. Hunninghake, H. R. Line, and R. G. Crystal. 1983. The alveolitis of pulmonary sarcoidosis: evaluation of natural history and alveolitis-dependent changes in lung function. Am. Rev. Respir. Dis. 128:256-265.
28. Hollinger, W. M., G. W. Staton, W. A. Fajman, M. J. Gilman, J. R. Pine, and I. J. Check. 1985. Prediction of therapeutic response in steroid-treated pulmonary sarcoidosis. Am. Rev. Respir. Dis. 132:65-69.
29. Israel, H., P. Karlin, H. Menduke, and O. DeLisser. 1986. Factors affecting outcome of sarcoidosis: influence of race, extrathoracic involvement, and initial radiologic lung lesions. Ann. N.Y. Acad. Sci. 465:609-618.
30. Keicho, N., K. Kitamura, F. Takaku, and H. Yotsumoto. 1990. Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest 98:1125-1129.
31. Ina, Y., K. Takada, T. Sato, M. Yamamoto, M. Noda, and M. Morishita. 1992. Soluble interleukin 2 receptor in patients with sarcoidosis: possible origin. Chest 102:1128-1133.
32. Strausz, J., J. Müller-Quernheim, and R. Ferlinz. 1989. Serumspiegel des sezernierten interleukin-2 rezeptor als ein aktivitätsparameter der sarkoidose. Disch. Med. Wochenschr. 114:744-749.
33. Liebermann, J., L. A. Schleissner, A. Nosal, A. Sasfre, and F. S. Mishkin. 1983. Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. Chest 84:522-528.
34. Ainslie, G. M., L. W. Poulter, and R. M. du Bois. 1989. Relation between immunocytological features of bronchoalveolar lavage fluid and clinical indices in sarcoidosis. Thorax 44:501-509.
35. Prior, C., R. A. Barbee, P. M. Evans, P. J. Townsend, Z. S. Primett, F. Fyhrquist, C. Grönhagen-Riska, and P. L. Haslam. 1990. Lavage versus serum measurement of lysozyme, angiotensin converting enzyme and other inflammatory markers in sarcoidosis. Eur. Respir. J. 3:1146-1154.